New drug vs standard care for HER2-mutant lung cancer
Treatments studied
Part of Lungs & breathing clinical trials.
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
- Your cancer must have a specific HER2 mutation (confirmed by a central lab).
- You must be between 18 and 75 years old, and your doctor expects you to live at least 12 more weeks.
- You need to be in fairly good health (able to do most daily activities) and have at least one tumor that can be measured on a scan.
- You cannot have had certain previous treatments, including those that target HER2 or certain types of antibody-drug conjugates.
- You cannot have certain other health problems, like uncontrolled infections, serious heart or lung disease, or brain metastases that have not been treated.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (BL-B01D1 plus a bispecific antibody) against the current standard chemotherapy and immunotherapy. It aims to see if the new combination works better for people with advanced non-squamous non-small cell lung cancer who haven't had treatment before.
This study tests a new drug combination, BL-M07D1 plus pembrolizumab (an immunotherapy), for people with a certain type of advanced lung cancer that has high levels of HER2 protein. The goal is to see if the combination is safe and effective for people who have not been treated with HER2-targeting drugs before.
This trial tests a new drug combination for people with advanced non-squamous non-small cell lung cancer who have not had treatment before. It compares the new drug with a standard immunotherapy, both given with chemotherapy, to see which is more effective.
This trial tests whether a new cancer drug called BL-M07D1, combined with pertuzumab, works better or as well as standard chemotherapy for advanced HER2-positive breast cancer that has spread or come back. HER2-positive means the cancer cells have high levels of a protein called HER2, which makes them grow faster.
This trial tests a new drug, BL-M07D1, against standard chemotherapy for people with HER2-low breast cancer that has spread or come back. It aims to find which treatment works better.
This trial compares a new combination of drugs (one that targets cancer cells and another that boosts the immune system) against a standard chemotherapy plus immune therapy combination. The goal is to see if the new approach works better as a first treatment for advanced squamous lung cancer.
Hear when a new Non-squamous Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.